* G1 Therapeutics Inc GTHX.OQ reported a quarterly
adjusted loss
of 20 cents per share for the quarter ended in March, higher
than the same quarter last year, when the company reported EPS
of -53 cents. The mean expectation of five analysts for the
quarter was for a loss of 21 cents per share. Wall Street
expected results to range from -22 cents to -20 cents per share.
* Revenue rose 11.8% to $14.48 million from a year ago;
analysts
expected $15.26 million.
* G1 Therapeutics Inc's reported EPS for the quarter was a
loss
of 20 cents.
* The company reported a quarterly loss of $10.22 million.
* G1 Therapeutics Inc shares had fallen by 12.7% this
quarter and
gained 23.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 27.3%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and 1 "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for G1 Therapeutics
Inc is $8.50
This summary was machine generated from LSEG data May 1 at 01:32
p.m. UTC. All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.21 -0.20 Beat
Dec. 31 2023 -0.28 -0.21 Beat
Sep. 30 2023 -0.33 -0.35 Missed
Jun. 30 2023 -0.22 0.14 Beat